Enbrel(etanercept)
Benepali, Enbrel, Erelzi, Eticovo, Nepexto (etanercept) is a protein pharmaceutical. Etanercept was first approved as Enbrel on . It is used to treat ankylosing spondylitis, juvenile arthritis, psoriatic arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat ankylosing spondylitis, arthritis, psoriasis, psoriatic arthritis, and rheumatoid arthritis amongst others. The pharmaceutical is active against tumor necrosis factor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Enbrel (discontinued: Enbrel, Erelzi, Eticovo)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| enbrel | Biologic Licensing Application | 2025-12-09 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
etanercept, Enbrel, Immunex Corporation | |||
| 2106-05-27 | Orphan excl. | ||
etanercept, Enbrel Mini, Immunex Corporation | |||
| 2106-05-27 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1438 | Injection, etanercept, 25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
Clinical
Clinical Trials
513 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 7 | 11 | 40 | 63 | 67 | 187 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 3 | 6 | 37 | 32 | 37 | 112 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 1 | 5 | 19 | 26 | 39 | 89 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 5 | 9 | 18 | 22 | 53 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | 1 | 7 | 8 | 19 | 35 |
| Spondylarthritis | D025241 | — | — | — | 3 | 3 | 9 | 11 | 25 |
| Juvenile arthritis | D001171 | EFO_1002007 | M08 | 1 | 3 | 10 | 2 | 6 | 20 |
| Spondylitis | D013166 | — | M46.9 | — | 2 | 3 | 5 | 7 | 16 |
| Inflammation | D007249 | MP_0001845 | — | — | 5 | 3 | 2 | 6 | 15 |
| Spondylarthropathies | D025242 | EFO_0000706 | M47 | — | 2 | 1 | 4 | 3 | 9 |
Show 23 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 8 | 11 | 3 | — | — | 15 |
| Graft vs host disease | D006086 | — | D89.81 | — | 5 | 2 | — | 1 | 8 |
| Neoplasms | D009369 | — | C80 | 3 | 2 | 1 | — | — | 5 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | 1 | — | 4 | 5 |
| Hypoglycemia | D007003 | — | E16.2 | 1 | 2 | 2 | — | — | 4 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | 1 | 1 | — | 2 | 4 |
| Follicular lymphoma | D008224 | — | C82 | — | — | 4 | — | — | 4 |
| Rheumatic diseases | D012216 | — | M79.0 | — | 1 | 1 | — | 1 | 3 |
| Musculoskeletal diseases | D009140 | — | — | — | 1 | 1 | — | 1 | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | 1 | — | 1 | 2 |
Show 32 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 11 | 2 | — | — | — | 13 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 4 | 1 | — | — | 1 | 6 |
| Necrosis | D009336 | — | — | — | 2 | — | — | 4 | 6 |
| Leukemia | D007938 | — | C95 | 2 | 5 | — | — | — | 5 |
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | 5 | — | — | — | 5 |
| Dementia | D003704 | EFO_0003862 | F03 | 1 | 1 | — | — | 1 | 3 |
| Hidradenitis suppurativa | D017497 | — | L73.2 | — | 2 | — | — | 1 | 3 |
| Asthma | D001249 | EFO_0000270 | J45 | — | 2 | — | — | 1 | 3 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | 2 | — | — | — | 2 |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | — | C92.2 | 1 | 2 | — | — | — | 2 |
Show 55 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | 2 | 3 |
| Cognitive dysfunction | D060825 | — | G31.84 | 1 | — | — | — | 1 | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 1 | 2 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 1 | — | — | — | — | 1 |
| Postmenopause | D017698 | — | — | 1 | — | — | — | — | 1 |
| Persian gulf syndrome | D018923 | EFO_0007430 | — | 1 | — | — | — | — | 1 |
| Occupational diseases | D009784 | — | — | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Bites and stings | D001733 | — | — | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Show 8 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | — | — | — | 2 | 2 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | — | — | 2 | 2 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | — | 2 | 2 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | — | 2 | 2 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 2 | 2 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | — | 2 | 2 |
| Papulosquamous skin diseases | D017444 | — | L40-L45 | — | — | — | — | 2 | 2 |
| Brain diseases | D001927 | — | G93.40 | — | — | — | — | 1 | 1 |
| Fatigue | D005221 | — | R53.83 | — | — | — | — | 1 | 1 |
| Enthesopathy | D000070676 | — | M77.9 | — | — | — | — | 1 | 1 |
Show 28 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Etanercept |
| INN | etanercept |
| Description | Etanercept, sold under the brand name Enbrel among others, is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. TNF-alpha is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha.
|
| Classification | Protein |
| Drug class | receptor molecules or membrane ligands, natural, modified or modified: tumor necrosis factor receptors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201572 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00005 |
| UNII ID | OP401G7OJC (ChemIDplus, GSRS) |
Target
Agency Approved
TNF
TNF
Organism
Homo sapiens
Gene name
TNF
Gene synonyms
TNFA, TNFSF2
NCBI Gene ID
Protein name
tumor necrosis factor
Protein synonyms
APC1 protein, Cachectin, TNF, macrophage-derived, TNF, monocyte-derived, TNF-a, TNF-alpha, tumor necrosis factor ligand 1F, Tumor necrosis factor ligand superfamily member 2, tumor necrosis factor-alpha, tumor necrotic factor alpha
Uniprot ID
Mouse ortholog
Tnf (21926)
tumor necrosis factor (P06804)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Benepali – Biogen
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Enbrel – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Enbrel – Amgen
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Etanercept – Organon
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Etanercept
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 33,023 documents
View more details
Safety
Black-box Warning
Black-box warning for: Enbrel
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
599,204 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use